Você procurou por: levertumorer (Dinamarquês - Inglês)

levertumorer
liver tumours

tyndtarmstumorer, levertumorer, kolorektale tumorer og pankreastumorer
small bowel, hepatic, colorectal and pancreatic tumours

levertumorer er højst sandsynligt forbundet med gnavernes specifikke enzyminduktion.
liver tumours are most likely related to enzyme induction specific to rodents.

nuværende eller tidligere levertumorer (benigne eller maligne).
presence or history of liver tumours (benign or malignant).

stigningen i forekomsten af benigne levertumorer hos mus var sandsynligvis et tilpasningsforhold.
the increased incidence of benign liver tumors in mice was likely an adaptive event.

sådanne leverskader er blevet sat i forbindelse med senere udvikling af levertumorer.
liver damage has been associated with subsequent development of liver tumours.

den øgede forekomst af benigne levertumorer hos mus var sandsynligvis et adaptivt tilfælde.
the increased incidence of benign liver tumors in mice was likely an adaptive event.

der blev observeret en stigning i incidensen af levertumorer i karcinogenicitetsstudier på rotter og mus.
an increased incidence of liver tumours was observed in carcinogenicity studies conducted in rats and mice.

det skyldes, at micafungin har vist sig at øge risikoen for, at rotter udvikler levertumorer.
this is because micafungin has been shown to increase the risk of liver tumours developing in rats.

hos mus udvikledes dosis- relateret ecl cellehyperplasi såvel som levertumorer og adenom af rete testis.
in mice dose-related gastric ecl cell hyperplasia developed as well as liver tumours and adenoma of rete testis.

i sjældne tilfælde er der rapporteret godartede levertumorer og endnu mere sjældent ondartede levertumorer hos brugere af coc.
in rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of cocs.

hos rotter og mus er der fundet levertumorer ved høje doser, hvilket kan tilskrives peroxisom-proliferation.
in rats and mice, liver tumours have been found at high dosages, which are attributable to peroxisome proliferation.

i carcinogenicitetsforsøg med mus blev der udviklet dosisrelateret gastrisk hyperplasi i ecl- celler samt levertumorer og adenom i rete testis.
in mouse carcinogenicity studies dose-related gastric ecl cell hyperplasia developed as well as liver tumours and adenoma of rete testis.

på grund af øget risiko for at udvikle levertumorer, må mycamine kun anvendes, hvis andre midler mod svampeinfektioner ikke er egnede.
because of a possible risk of liver tumours, mycamine is only to be used if other antifungal medicines are not appropriate.

der er i sjældne tilfælde rapporteret om benigne levertumorer, og endnu sjældnere om tilfælde af maligne levertumorer hos p-pillebrugere.
in rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of cocs.

for at mindske risikoen for adaptiv regenerering og mulig dannelse af levertumorer anbefales der tidlig seponering ved signifikante og vedvarende forhøjede værdier af alat/asat.
to minimise the risk of adaptive regeneration and potentially subsequent liver tumour formation, early discontinuation in the presence of significant and persistent elevation of alt/ast is recommended.

vær ekstra forsigtig med at bruge mycamine hos rotter fører langvarig behandling med micafungin til leverskade og efterfølgende svulster i leveren (levertumorer).
take special care with mycamine in rats, long-term treatment with micafungin led to liver damage and subsequent liver tumours.

43 langtids karcinogenicitetsforsøg af lopinavir/ ritonavir i mus viste en ikke genotoksisk, mitogen induktion af levertumorer, som generelt menes at have lille relevans for mennsker.
41 long-term carcinogenicity studies of lopinavir/ ritonavir in mice revealed a nongenotoxic, mitogenic induction of liver tumours, generally considered to have little relevance to human risk.

perorale langtidsundersøgelser i rotter, mus og hamstere - skønt ikke alle lige gode -viser klart, at stoffet frembringer godartede levertumorer og levercellekaroinomer.
the oral long-term studies in rats, mice and hamsters, although not all adequate, show clearly that the substance produces benign liver tumours and hepatocellular carcinomas.

plasmaeksponeringen ved den formodede tærskelværdi for tumorudvikling hos rotter (dvs. den dosis, hvor der ikke blev fundet fah og levertumorer) lå inden for det kliniske eksponeringsinterval.
the plasma exposure at the assumed threshold for tumour development in rats (i.e. the dose where no fah and liver tumours were detected) was in the same range as the clinical exposure.